Tevogen (TVGN) Interest Expenses (2022 - 2025)
Tevogen Bio Holdings' (TVGN) quarterly Interest Expenses came in at $18.9 million in Q4 2025, up 1979.27% YoY from $908888.0 in Q4 2024, and up 76812.6% on a QoQ basis from $24571.0 in Q1 2025.
Tevogen (TVGN) Interest Expenses (2022 - 2025) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 4 years of Interest Expenses data on file, last reported at $18.9 million in Q4 2025.
- Quarterly Interest Expenses rose 1979.27% year-over-year to $18.9 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $24571.0 (down 97.4% YoY) and the FY2025 annual result came in at $18.9 million, up 1654.5% from the prior year.
- Interest Expenses improved to $18.9 million in Q4 2025, from $24571.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $18.9 million in Q4 2025 to a low of $12459.0 in Q3 2024.
- A 4-year average of $2.8 million and a median of $299943.0 in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2024 — Interest Expenses sank 95.85% — and 2025, when it soared 1979.27%.
- Tracing TVGN's Interest Expenses over 4 years: stood at $4.2 million in 2022, then sank by 92.4% to $317525.0 in 2023, then jumped by 186.24% to $908888.0 in 2024, then soared by 1979.27% to $18.9 million in 2025.
- The last three Interest Expenses figures came in at $18.9 million (Q4 2025), $24571.0 (Q1 2025), and $908888.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Tevogen | 25.62 Mn | 25.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18.90 Mn |
| Dec 31, 2025 | 18.90 Mn |
| Mar 31, 2025 | 24,571.00 |
| Mar 31, 2025 | 24,571.00 |
| Dec 31, 2024 | 908,888.00 |
| Dec 31, 2024 | 908,888.00 |
| Sep 30, 2024 | 12,459.00 |
| Sep 30, 2024 | 12,459.00 |
| Mar 31, 2024 | 155,786.00 |
| Mar 31, 2024 | 155,786.00 |
| Dec 31, 2023 | 317,525.00 |
| Dec 31, 2023 | 317,525.00 |
| Sep 30, 2023 | 299,943.00 |
| Sep 30, 2023 | 299,943.00 |
| Mar 31, 2023 | 288,997.00 |
| Mar 31, 2023 | 288,997.00 |
| Dec 31, 2022 | 4.18 Mn |
| Dec 31, 2022 | 4.18 Mn |